CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals involved in the treatment of cancer.
  
  LEARNING OBJECTIVES

  • Consider research data, clinical investigator perspectives and available guideline recommendations to individualize therapy for patients with localized or advanced breast, gastrointestinal, genitourinary, gynecologic, lung and select hematologic cancers in the newly diagnosed or relapsed/refractory settings.
  • Recognize oncogenic pathways mediating the pathogenesis of tumors in unique patient subsets, and recall published and emerging data with commercially available and experimental agents exploiting these pathways.
  • Develop a long-term care plan for patients with diverse hematologic cancers and solid tumors, considering age, performance status, tumor-specific biomarker profile, prior exposure to systemic therapy, symptomatology and personal goals of treatment.
  • Discuss the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals or presented at major oncology conferences.
  • Recall clinical trial data with FDA-approved and investigational agents for patients with localized, locally advanced or metastatic breast, gastrointestinal, genitourinary, gynecologic, lung and select hematologic cancers, and, as applicable, refer eligible patients for clinical trial participation.
  • Appraise the common and rare side effects associated with approved and investigational therapeutic agents for cancer, and use this information to develop supportive management plans for patients.
  • Apply clinical research findings in the determination of best-practice selection and sequencing of available treatment modalities for patients with breast, gastrointestinal, genitourinary, gynecologic, lung and select hematologic cancers.
  • Recognize the mechanisms of action, efficacy and safety of approved and investigational therapies to determine the current and potential utility of those agents in clinical practice.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
  
  Thomas A Abrams, MD
  Senior Physician
  Dana-Farber Cancer Institute
  Assistant Professor of Medicine
  Harvard Medical School
  Director, Liver Tumor Center
  Boston, Massachusetts
  
  Advisory Committee: Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck; Consulting Agreements: Bristol-Myers Squibb Company, Servier; Ownership Interest: Biogen, Guardant Health, Jounce Therapeutics.
  
  John N Allan, MD
  Assistant Professor of Medicine
  Weill Cornell Medicine
  New York, New York
  
  Advisory Committee: AbbVie Inc, Ascentage Pharma, Epizyme, Genentech, a member of the Roche Group, Janssen Biotech Inc, Pharmacyclics LLC; Consulting Agreement: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene, Janssen Biotech Inc, Pharmacyclics LLC; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, TG Therapeutics Inc.
  
  Deborah K Armstrong, MD
  Professor of Oncology
  Professor of Gynecology and Obstetrics
  Skip Viragh Outpatient Cancer Building
  Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
  Baltimore, Maryland
  
  Advisory Committee: AbbVie Inc, Cue Biopharma, Eisai Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Pfizer Inc, Syndax Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.
  
  Arjun Balar, MD
  Associate Professor, Department of Medicine
  Director, Genitourinary Medical Oncology Program
  Medical Director, Clinical Trials Office
  NYU Perlmutter Cancer Center
  New York, New York
  
  Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Pfizer Inc, Seagen Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Pfizer Inc, Seagen Inc; Ownership Interest: GT Biopharma Inc.
  
  Virginia F Borges, MD, MMSc
  Professor of Medicine with Tenure
  John C and Patricia Young-Connor Endowed Chair in Young Women’s Breast Cancer
  Deputy Head, Division of Medical Oncology
  Director, Breast Cancer Research Program and
  Young Women’s Breast Cancer Translational Program
  University of Colorado Cancer Center
  Aurora, Colorado
  
  Consulting Agreement: Seagen Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Merck, Pfizer Inc, Seagen Inc.
  
  Harold J Burstein, MD, PhD
  Institute Physician, Dana-Farber Cancer Institute
  Professor of Medicine, Harvard Medical School
  Boston, Massachusetts
  
  No relevant conflicts of interest to disclose.
  
  Robert Dreicer, MD, MS
  Section Head, Medical Oncology
  Deputy Director, University of Virginia Cancer Center
  Associate Director for Clinical Research
  Professor of Medicine and Urology
  University of Virginia School of Medicine
  Charlottesville, Virginia
  
  Advisory Committee: Astellas, Bayer HealthCare Pharmaceuticals, Eisai Inc, EMD Serono Inc, Exelixis Inc, Gilead Sciences Inc, Hinova Pharmaceuticals Inc, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Merck, Myovant Sciences, Pfizer Inc, PropellaTherapeutics Inc, TavantaTherapeutics; Contracted Research: Arvinas, Exelixis Inc, Seagen Inc; Data and Safety Monitoring Board/Committee: Hinova Pharmaceuticals Inc.
  
  Justin F Gainor, MD
  Director, Center for Thoracic Cancers at Massachusetts General Hospital
  Director of Targeted Immunotherapy in the Henri and BelindaTermeer Center for Targeted Therapies
  Associate Professor of Medicine at Harvard Medical School
  Massachusetts General Hospital
  Boston, Massachusetts
  
  Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Gilead Sciences Inc, Helsinn Healthcare SA, Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Oncorus, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Oncology; Contracted Research: Adaptimmune, ALX Oncology, Array BioPharma Inc, a subsidiary of Pfizer Inc, Blueprint Medicines, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Jounce Therapeutics, Merck, Moderna, Novartis, Scholar Rock, Takeda Oncology, Tesaro, A GSK Company; Employment (Immediate Family Member): Ironwood Pharmaceuticals.
  
  J Randolph Hecht, MD
  Professor of Clinical Medicine
  Director, UCLA GI Oncology Program
  Carol and Saul Rosenzweig Chair in Cancer Therapies Development
  Santa Monica, California
  
  Advisory Committee: Actym Therapeutics, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Mirati Therapeutics, Rafael Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Amgen Inc, Astellas, Merck, Mirati Therapeutics, Tesaro, A GSK Company.
  
  Corey J Langer, MD
  Director of Thoracic Oncology
  Abramson Cancer Center
  Professor of Medicine
  Perelman School of Medicine
  University of Pennsylvania
  Philadelphia, Pennsylvania
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Exelixis Inc, Genentech, a member of the Roche Group, Merck, Novocure Inc, Regeneron Pharmaceuticals Inc, Takeda Oncology; Consulting Agreements: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Hospira Inc, Jazz Pharmaceuticals Inc, Merck, Novartis, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Oncology; Contracted Research: Advantagene Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Inovio Pharmaceuticals Inc, Lilly, Mirati Therapeutics, Takeda Oncology, Trizell; Data and Safety Monitoring Board/Committee: Lilly, Oncocyte.
  
  Krishnansu S Tewari, MD
  Professor and Division Director
  Division of Gynecologic Oncology
  University of California, Irvine
  Irvine, California
  
  Advisory Committee: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Merck, Tesaro, A GSK Company; Contracted Research (to Institution): Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Iovance Biotherapeutics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Merck, Tesaro, A GSK Company.
  
  Sonali M Smith, MD
  Elwood V Jensen Professor of Medicine
  Chief, Section of Hematology/Oncology
  Co-Leader, Cancer Service Line
  Co-Director, Lymphoma Program
  The University of Chicago
  Chicago, Illinois
  
  Consulting Agreements: Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, MorphoSys, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Celgene Corporation, Epizyme Inc, Forty Seven Inc, Genentech, a member of the Roche Group, Karyopharm Therapeutics, Novartis, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, TG Therapeutics Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Amgen Inc, Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb Company, Exact Sciences, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Merck, Pharmacyclics LLC, an AbbVie Company, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Sanofi Genzyme.
  
  Release date: July 2021
  Expiration date: July 2022